Second of two planned phase III pivotal trials of autologous cell therapy utilising tumour infiltrating lymphocytes [Contego] as second-line therapy in patients with stage IV metastatic melanoma.

Trial Profile

Second of two planned phase III pivotal trials of autologous cell therapy utilising tumour infiltrating lymphocytes [Contego] as second-line therapy in patients with stage IV metastatic melanoma.

Planning
Phase of Trial: Phase III

Latest Information Update: 13 Oct 2011

At a glance

  • Drugs LN 144 (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Most Recent Events

    • 13 Oct 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top